2C-T-7

2C-T-7 is a psychedelic phenethylamine of the 2C family. In his book PiHKAL (Phenethylamines i Have Known And Loved), Alexander Shulgin lists the dosage range as 10 to 30 mg. 2C-T-7 is generally taken orally, and produces psychedelic and entheogenic effects that last 8 to 15 hours. Up until Operation Web Tryp and three deaths, two of which involved the use of other drugs in addition to 2C-T-7, and one which involved an excessive insufflated dose, 2C-T-7 was sold commercially in Dutch and Japanese smartshops and online. It is known on the streets as "Blue Mystic". There has been little real research done on this chemical other than Shulgin's comments in PiHKAL and a few small animal studies mostly aimed at detecting metabolites.

Pharmacology
The mechanism that produces the psychedelic and entheogenic effects of 2C-T-7 is most likely to result from action as a 5-HT2A serotonin receptor agonist in the brain, a mechanism of action shared by all of the hallucinogenic tryptamines and phenethylamines.

As the 2,5-desmethoxy derivative of 2C-T-7 has been shown to be a moderate monoamine oxidase A inhibitor, 2C-T-7 may likewise have MAO-A inhibitory effects. If 2C-T-7 does have MAO-A inhibitory effects, then this could indicate that 2C-T-7 is more likely to induce serotonin syndrome, especially at high dosages, than other serotonergic hallucinogens, which may contribute to the toxic effects of ephedrine and MDMA which have been shown to increase following MAO inhibition. (See: Deaths, infra)

Effects


2C-T-7 is psychedelic. In PiHKAL, Shulgin writes that the hallucinations are unique. He also comments on the tenseness of his muscles and his change in voice tone, which lasted some days. Shulgin suggested reading about amateur research on 2C-T-7's effects. Erowid gives the following effects list:

Positive

 * sense of well-being (enhanced lucidity, sense of inner peace)
 * emotional opening
 * significant closed and open eye visuals
 * increased appreciation of music

Neutral

 * sexual dysfunction
 * general change in consciousness (as with most psychoactives)
 * pupil dilation
 * change in perception of time
 * visual hallucinations
 * auditory hallucinations

Negative

 * arrhythmia
 * paranoia
 * psychotic break
 * nausea and vomiting
 * muscle tension
 * insomnia
 * muscle tremors and/or convulsions
 * memory loss (at higher doses)
 * potential trigger of HPPD
 * delirium (at higher doses) (potentially dangerous)
 * violent behavior (at higher doses)
 * tachycardia

The drug can be taken orally or snorted, although nasal administration is reported to be extremely painful. Use of 2C-T-7 as a nootropic at low doses of 1–10 mg has been reported, and it may be useful for this purpose in a similar manner to LSD, which shows modest stimulant and nootropic effects at doses of 10 µg.

Deaths
The Partnership for a Drug-Free America reports that 2C-T-7 can be lethal even in small doses, however; they provide no source for their claim and of the three known deaths of 2C-T-7 intoxicated individuals, all involved either excessive insufflated doses or the concomitant ingestion of other stimulants such as ephedrine and MDMA. There have been at least three reported deaths related to 2C-T-7 use as of August, 2007, mainly at insufflated doses of 30 mg or more or combined with stimulants such as MDMA, as well as a number of very uncomfortably intense effects and hospitalizations, these mostly followed insufflation of 2C-T-7. In January 2002, Rolling Stone published an article about 2C-T-7 entitled "The New (legal) Killer Drug", although the legal status of the drug was misrepresented in the article, as 2C-T-7 was already illegal under the United States' analog act. A detailed response on the website Disinformation challenged the accuracy of much of the reporting in that Rolling Stone article.

All of these known deaths of individuals under the influence of 2C-T-7, therefore, occurred in those known either to be intoxicated with potentially deadly stimulants such as ephedrine or MDMA or after the individual insufflated an excessive amount of 2C-T-7- excessive being an amount greater than necessary to induce the full range of the drug's effects, such as the reported 35 mg insufflated dose taken by the individual who died in the Fall of 2000. This reported dose was characterized as "excessive" by the US DEA. Additionally, ephedrine, itself an MAO inhibitor, and MDMA may interact with any monoamine oxidase inhibition by 2C-T-7, which is presently speculative, to increase the cardiotoxicity of MDMA or ephedrine, which together were known to be present in two of the three deaths of 2C-T-7-intoxicated individuals. Ephedrine's cardiovascular effects have previously been shown to be potentiated by some MAO-A inhibitors

Legality
Around the year 2000, 2C-T-7 began to change from an obscure chemical to a drug used at parties and clubs in North America and Europe as it became available through a number of grey-market commercial vendors. This aroused the attention of the authorities, and since many countries have scheduled the chemical.

Australia
In Australia, 2C-T-2 and 2C-T-7 are covered by the country's analogue drug laws.

Canada
2C-T-7 is unscheduled in Canada.

The Netherlands
The Netherlands was the first country in the world to ban 2C-T-7, after being sold in smartshops for a short period. After 2C-T-2 was first banned, 2C-T-7 quickly appeared on the market, but was soon banned as well. 2C-T-7 is a list I drug of the Opium Law.

Sweden
2C-T-2 became commercially available in Sweden in the summer of 1998, being sold in smartshops similar to those in the Netherlands. On April 1, 1999, both 2C-T-2 and 2C-T-7, along with MBDB, BDB, 2C-B and PMMA, were banned in Sweden. This was not done by appending these drugs to the country's normal drug laws, but by passing a new law, "Förordning (1999:58) om förbud mot vissa hälsofarliga varor," which banned the drugs as being materials dangerous to health.

UK
In 1999, Alexander Shulgin was sent a copy of a letter from the British Home Office to several of its administrative associates which in effect placed all compounds listed in PiHKAL into Class A.

US
On September 20, 2002, 2C-T-7 was classified as a Schedule I substance in the United States by an emergency ruling by the DEA. On March 18, 2004, the DEA published a Final Rule in the Federal Register permanently placing 2C-T-7 in Schedule I. (69 FR 12794).